Wynne-Jones IP celebrates ‘exceptional’ results in training academy’s first successful year
Ten flourishing staff members have achieved ‘exceptional’ exam success in Wynne-Jones IP’s first successful year of running their training academy.
Find the right content for you
Ten flourishing staff members have achieved ‘exceptional’ exam success in Wynne-Jones IP’s first successful year of running their training academy.
In 2017 we celebrate Innovation – Improving Lives. Every day, ordinary people are producing extraordinary new things to change the world for the better. Happy World IP Day!
Our survey results - What does innovation mean to you?
Innovation – is it just an overused word? Or does it lead to radical economic progression and advancement?
Either way most of us take innovation for granted – the latest Android mobile phone, games console, or medical advancement, is something which many feel is inevitable.
However, many innovations wouldn’t exist without intellectual property (IP). These include trade marks, patents, designs and copyright, which serve to protect and encourage the progression of innovation.
So, to mark World IP Day, which highlights the vital role intellectual property plays in innovation, leading Cardiff-based IP firm Wynne Jones IP, has identified the top six innovations waiting to revolutionise your home, health, and happiness.
Vicki & Phil's Innovation Showcase looks at how the inventors behind some fantastic ideas have used IP and Product Design to great effect to protect and develop appealing, manufacturable and marketable products.
Ten flourishing staff members have achieved ‘exceptional’ exam success in Wynne-Jones IP’s first successful year of running their training academy.
With 2015 sales of US$1.6Bn and 2017 projected sales of US$2Bn, Bristol-Myers Squibb’s (BMS’) anti-cancer drug dasatinib (Sprycel®) is highly successful and of great interest to competitors. A February 2017 decision from a Technical Board of Appeal at the EPO (European Patent Office) has resulted in the patent covering dasatinib being revoked. But why?
European patent 1169038 [1] covering dasatinib was granted in 2012, opposed in 2013, revoked in January 2016, and the revocation upheld in an appeal deci
By clicking any link on this page you are giving your consent for us to set cookies.